Search

Repligen Corp

Closed

SectorHealthcare

178.35 1.04

Overview

Share price change

24h

Current

Min

174.22

Max

177

Key metrics

By Trading Economics

Income

-3.3M

5M

Sales

9.9M

204M

P/E

Sector Avg

236.315

48.735

EPS

0.54

Profit margin

2.453

Employees

2,000

EBITDA

14M

46M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+15.44% upside

Dividends

By Acuity

Next Earnings

27 paź 2026

Market Stats

By TradingEconomics

Market Cap

3.6B

11B

Previous open

177.31

Previous close

178.35

Repligen Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 paź 2026, 19:36 UTC

News

Canaccord Genuity raises Repligen Corp's price target to $180.00 from $145.00 while maintaining a Hold rating, reflecting a positive reassessment of the company's value.

16 paź 2026, 22:01 UTC

Repligen Corp is trading lower in after-market hours, following a notable decline since Friday's close amid unusual volatility and positioning near its one-month range low.

15 paź 2026, 20:07 UTC

Repligen Corp shares advanced, reaching a peak before the session's conclusion.

14 paź 2026, 20:07 UTC

Repligen Corp shares are advancing, benefiting from broader market gains, despite pulling back from earlier session highs. The stock is higher since Tuesday's close.

13 paź 2026, 20:07 UTC

News

Repligen Corp shares are advancing as the company prepares to report its third-quarter 2026 financial results on October 27, 2026.

12 paź 2026, 21:03 UTC

Repligen Corp shares advanced during after-market hours on Monday, moving from a low return to a high return.

9 paź 2026, 20:01 UTC

Repligen Corp shares are sharply higher, continuing an upward trajectory since Thursday's close, supported by positive movement in the broader life sciences sector.

8 paź 2026, 20:07 UTC

Repligen Corp shares fell sharply, continuing a downward trend with three consecutive sessions down, despite a brief recovery earlier in the session.

7 paź 2026, 20:01 UTC

News

Repligen Corp. finalized its $1.5 billion acquisition of BioLife Solutions, but shares fell sharply amid ongoing declines following a prior session drop.

6 paź 2026, 21:01 UTC

Repligen Corp's shares traded modestly higher in after-market hours, marking a peak since Tuesday's close despite remaining below the 20-day moving average.

5 paź 2026, 22:15 UTC

News

Repligen Corp plans to acquire BioLife Solutions, contributing to a modest after-market hours gain as the stock remains above its 20-day moving average.

2 paź 2026, 20:07 UTC

Repligen Corp's shares are advancing, reflecting a broader market trend, maintaining strong performance above the 20-day moving average amid notable intraday volatility.

1 paź 2026, 20:02 UTC

Repligen Corp shares fell sharply, breaking a trend of higher daily closes and diverging from recent upward momentum.

30 wrz 2026, 21:01 UTC

Repligen Corp is advancing in after-market trading, reflecting broader market gains amid revised Q2 GDP growth and stronger consumer spending.

29 wrz 2026, 23:25 UTC

Repligen Corp has seen a modest decline in after-market trading, retracing from earlier gains and reflecting unusual volatility compared to Tuesday's close.

28 wrz 2026, 20:07 UTC

Repligen Corp shares are higher today, maintaining an upward trajectory since Friday's close, supported by strong performance in the life sciences sector.

25 wrz 2026, 21:01 UTC

Repligen Corp's shares advanced modestly higher during after-market hours, reflecting strong performance and favorable conditions above their 20-day moving average.

24 wrz 2026, 22:05 UTC

Repligen Corp's shares advanced modestly higher in after-market trading, currently 9.33% above its 20-day moving average and near the upper end of its one-month range.

23 wrz 2026, 23:46 UTC

Repligen Corp's stock declined in after-market trading, hitting its lowest point of the day after Wednesday's close, despite remaining above its 20-day moving average.

22 wrz 2026, 20:13 UTC

Repligen Corp's shares advanced modestly in after-market trading, maintaining strength and staying significantly above its 20-day moving average.

21 wrz 2026, 20:06 UTC

Correlated Moves

Repligen Corp is advancing, supported by sympathy with Agilent Technologies' new product launch, and is performing strongly above its 20-day moving average.

18 wrz 2026, 19:16 UTC

Repligen Corp shares fell modestly, fluctuating between small gains and losses, despite remaining above the 20-day moving average and near the one-month range.

16 wrz 2026, 19:16 UTC

Repligen Corp shares fell after briefly rising, retracing from earlier gains in Wednesday's trading session following three consecutive sessions of increases.

15 wrz 2026, 20:07 UTC

Correlated Moves

Repligen Corp is higher today, moving alongside Revvity Inc amid a broader market decline following a drop in the NY Empire State Manufacturing Index.

14 wrz 2026, 19:46 UTC

Repligen Corp shares are higher today, continuing an upward trend since Friday. The stock has fluctuated within a range during the session.

11 wrz 2026, 21:01 UTC

Repligen Corp shares are higher in after-market trading, continuing an upward trend since Friday's close. The stock remains below its 20-day moving average.

10 wrz 2026, 20:07 UTC

Repligen Corp shares are lower amid broader market declines following the European Central Bank's interest rate hike and rising Treasury yields.

9 wrz 2026, 20:07 UTC

Repligen Corp shares are lower during Wednesday's session, with no specific news identified. The stock remains significantly below its 20-day moving average.

8 wrz 2026, 22:21 UTC

Repligen Corp shares declined in after-market trading, falling further from Tuesday's close and remaining near the lower end of their one-month trading range.

2 wrz 2026, 19:26 UTC

Repligen Corp shares are higher during Wednesday's session, reaching a session high earlier today. The stock shows resilience amid broader market geopolitical tensions.

Peer Comparison

Price change

Repligen Corp Forecast

Price Target

By TipRanks

15.44% upside

12 Months Forecast

Average 202.5 USD  15.44%

High 225 USD

Low 180 USD

Based on 9 Wall Street analysts offering 12 month price targets forRepligen Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

8

Buy

1

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Repligen Corp

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
help-icon Live chat